| Literature DB >> 27668119 |
Jie Fang1, Kehui Yi2, Mingwei Guo3, Xingkai An1, Hongli Qu1, Qing Lin1, Min Bi1, Qilin Ma4.
Abstract
Background. Parkinson's disease (PD) is an age-related neurodegenerative disease affected by multiple genetic and environmental factors. We performed a case-control study on candidate gene to scrutinize whether genetic variants in LRRK2, SNCA, and ITGA8 genes could be associated with sporadic PD in Chinese Han population. Methods. Five single-nucleotide polymorphisms (SNPs) of LRRK2 (rs1491942), SNCA (rs2301134, rs2301135, and rs356221), and ITGA8 (rs7077361) were selected and genotyped among 583 unrelated PD patients and 558 healthy controls. Results. Rs1491942 of LRRK2 gene had a significantly higher genotype frequency (P = 3.543E - 09) and allelic G/C frequencies (P = 2.601E - 10) in PD patients than controls. Rs2301135 of SNCA gene also showed an obvious difference in genotype frequency (P = 4.394E - 07) and allelic G/C frequencies (P = 9.116E - 13) between PD patients and controls. SNPs rs2301134 and rs356221 of SNCA gene and rs7077361 of ITGA8 gene lacked the significant association with the susceptibility of PD in Chinese Han population. Conclusions. Our study firstly expresses that rs1491942 of LRRK2 and rs2301135 of SNCA gene are substantially associated with sporadic Parkinson's disease in Chinese Han population.Entities:
Year: 2016 PMID: 27668119 PMCID: PMC5030423 DOI: 10.1155/2016/3474751
Source DB: PubMed Journal: Parkinsons Dis ISSN: 2042-0080
Demographic characteristics of Parkinson's disease (PD) cases and controls.
| Characteristics | Cases = 583 | Controls = 553 | ||
|---|---|---|---|---|
| Gender ( | ||||
| Female | 320 | 54.9 | 286 | 51.7 |
| Male | 263 | 45.1 | 267 | 48.3 |
| Age at collection (mean, SD)† | 65.10 | 8.90 | 65.37 | 9.03 |
| Age at onset ( | ||||
| <50 | 131 | 22.5 | n.a. | n.a. |
| ≧50 | 452 | 77.5 | n.a. | n.a. |
All the subjects were ethnic Hans; PD compared with controls by gender: P > 0.05; †PD compared with controls by age: P > 0.05; n.a.: not applicable.
PCR and Snapshot probe primer sequences.
| Polymorphisms | Primers | Sequence 5′ → 3′ |
|---|---|---|
| LRRK2 | ||
| rs1491942 | Forward | CAGGCTTGGGCAATTTCTAA |
| Reverse | GCCTATTGTGCTTCCTGCTC | |
| Probe | 40Ts+CAGGCTCCCCTGGGTT | |
|
| ||
| SNCA | ||
| rs2301134 | Forward | ATCACGCTGGATTTGTCTCC |
| Reverse | CACGGTCACAGGTTACAACG | |
| Probe | 41Ts+GACTCTTCCTTAGTAGTCTCCC | |
| rs356221 | Forward | TGCCATAGAAACAACGAGGA |
| Reverse | TTGAAGAACCCAAAATGCAA | |
| Probe | 24Ts+AAGAGAAGCCATCCTAGT | |
| rs2301135 | Forward | ACTTAACGTGAGGCGCAAAA |
| Reverse | CGTCCTCCTCCTCCTAGTCC | |
| Probe | 54Ts+CCGGGAGAGGGGCGGG | |
|
| ||
| IGTA8 | ||
| rs7077361 | Forward | TGCGAAAACTATTTGGTGAAA |
| Reverse | CCCACCCACCAAATCTCTAA | |
| Probe | 31Ts+GAAATCATCTAGGGGATA | |
Comparison of the genotype frequencies and the allele frequencies of LRRK2, SNCA, and ITGA8 polymorphisms.
| Gene SNP | Group | Genotype |
| Allele Min/Maj | MAFa | MAFb | OR (95% CI) |
| Powerc | |||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| CC | GC | GG | G/C | |||||||||||
|
| ||||||||||||||
| rs1491942 | Patients total | 291 | 49.9 | 240 | 41.2 | 52 | 8.9 | 0.84 | 344/822 | 0.30 | 0.36 | 1.884 (1.546–2.297) | 2.60 | 1.00 |
| Controls total | 372 | 67.3 | 161 | 29.1 | 20 | 3.6 | 0.67 | 201/905 | 0.18 | |||||
| EOPD | 65 | 49.6 | 54 | 41.2 | 12 | 9.2 | 0.84 | 78/184 | 1.924 (1.244–2.976) | 3.03 | ||||
| Controls < 50 y | 74 | 68.5 | 29 | 26.9 | 5 | 4.6 | 0.33 | 39/177 | ||||||
| LOPD | 226 | 50.0 | 186 | 41.2 | 40 | 8.8 | 0.82 | 266/638 | 1.874 (1.500–2.340) | 2.46 | ||||
| Controls ≧ 50 y | 298 | 67.0 | 132 | 29.7 | 15 | 3.4 | 0.87 | 162/728 | ||||||
|
| ||||||||||||||
| GG | AG | AA | A/G | |||||||||||
|
| ||||||||||||||
|
| ||||||||||||||
| rs2301134 | Patients total | 437 | 75.0 | 132 | 22.6 | 14 | 2.4 | 0.29 | 160/1006 | 0.14 | 0.20 | 1.237 (0.964–1.588) | 9.43 | 0.42 |
| Controls total | 436 | 78.8 | 108 | 19.5 | 9 | 1.6 | 0.40 | 126/980 | 0.11 | |||||
| EOPD | 97 | 74.0 | 32 | 24.4 | 2 | 1.5 | 1.00 | 36/226 | 1.561 (0.875–2.786) | 1.29 | ||||
| Controls < 50 y | 88 | 81.5 | 20 | 18.5 | 0 | 0.0 | 0.59 | 20/196 | ||||||
| LOPD | 340 | 75.2 | 100 | 22.1 | 12 | 2.7 | 0.16 | 124/780 | 1.176 (0.891–1.552) | 2.52 | ||||
| Controls ≧ 50 y | 348 | 78.2 | 88 | 19.8 | 9 | 2.0 | 0.25 | 106/784 | ||||||
|
| ||||||||||||||
| AA | TA | TT | T/A | |||||||||||
|
| ||||||||||||||
| rs356221 | Patients total | 210 | 36.0 | 282 | 48.4 | 91 | 15.6 | 0.86 | 464/702 | 0.40 | 0.40 | 1.167 (1.985–1.382) | 7.50 | 0.45 |
| Controls total | 231 | 41.8 | 244 | 44.1 | 78 | 14.1 | 0.31 | 400/706 | 0.36 | |||||
| EOPD | 43 | 32.8 | 67 | 51.1 | 21 | 16.0 | 0.59 | 109/153 | 1.286 (0.887–1.864) | 1.84 | ||||
| Controls < 50 y | 46 | 42.6 | 47 | 43.5 | 15 | 13.9 | 0.67 | 77/139 | ||||||
| LOPD | 167 | 36.9 | 215 | 47.6 | 70 | 15.5 | 1.00 | 355/549 | 1.135 (0.938–1.374) | 1.93 | ||||
| Controls ≧ 50 y | 185 | 41.6 | 197 | 44.3 | 63 | 14.2 | 0.36 | 323/567 | ||||||
|
| ||||||||||||||
| CC | GG | G/C | ||||||||||||
|
| ||||||||||||||
| rs2301135 | Patients total | 544 | 93.3 | 39 | 6.7 | <0.05 | 78/1088 | 0.07 | 0.19 | 7.857 (4.046–15.258) | 9.12 | 1.00 | ||
| Controls total | 548 | 99.1 | 5 | 0.9 | <0.05 | 10/1096 | 0.01 | |||||||
| EOPD | 129 | 98.5 | 2 | 1.5 | <0.05 | 4/258 | 1.016 (1.000–1.031) | 1.30 | ||||||
| Controls < 50 y | 108 | 100.0 | 0 | 0.0 | <0.05 | 0/216 | ||||||||
| LOPD | 415 | 91.8 | 37 | 8.2 | <0.05 | 74/830 | 7.846 (4.026–15.288) | 1.45 | ||||||
| Controls ≧ 50 y | 440 | 98.9 | 5 | 1.1 | <0.05 | 10/880 | ||||||||
|
| ||||||||||||||
| TT | CT | C/T | ||||||||||||
|
| ||||||||||||||
|
| ||||||||||||||
| rs7077361 | Patients total | 580 | 99.5 | 3 | 0.5 | 1.00 | 3/1163 | 0.00 | 0.00 | 2.85 (0.296–27.443) | 6.25 | 0.34 | ||
| Controls total | 552 | 99.8 | 1 | 0.2 | 1.00 | 1/1105 | 0.00 | |||||||
| EOPD | 131 | 100.0 | 0 | 0.0 | <0.05 | 0/262 | 0.995 (0.986–1.004) | 4.52 | ||||||
| Controls < 50 y | 107 | 99.1 | 1 | 0.9 | 1.00 | 0/0 | ||||||||
| LOPD | 449 | 99.3 | 3 | 0.7 | 1.00 | 3/449 | 1.003 (1.000–1.007) | 2.50 | ||||||
| Controls ≧ 50 y | 445 | 100.0 | 0 | 0.0 | <0.05 | 0/445 | ||||||||
EOPD: early onset Parkinson's disease; LOPD: late-onset Parkinson's disease; P HWE: P value obtained in the Hardy-Weinberg equilibrium (HWE) test; ∗: significant P value obtained in the case-control analysis; Min: minor; Maj: major; MAF: minor allele frequency; a: this study; b: 1000 genomes (Southern Han Chinese); c: power was calculated by Power and Sample Size Calculations version 3.1.2.